Navigation Links
Tarsa Therapeutics Presents Positive Efficacy and Safety Data Comparing Its Oral Calcitonin to Nasal Calcitonin and Placebo in Phase III Osteoporosis Treatment Trial
Date:9/19/2011

ood and Drug Administration and to submitting a Marketing Authorization Application to the European Medicines Agency thereafter.  We also are advancing our ongoing Phase Il trial in osteoporosis prevention, an indication for which our oral calcitonin could be especially relevant."

Tarsa's oral calcitonin is also being assessed in a double-blind Phase II study comparing the OSTORA tablet to placebo in postmenopausal women who have low bone mass (osteopenia) and are at increased risk of fracture.  This proof-of-concept study is evaluating the ability of oral calcitonin to prevent osteoporosis and maintain bone mass in this population.  

Tarsa is developing its OSTORA oral calcitonin under a licensing agreement with Unigene Laboratories that provides Tarsa with exclusive development and worldwide commercialization rights to Unigene's oral calcitonin product, with the exception of China.  For more information on Unigene, see www.unigene.com.

The American Society for Bone and Mineral Research 2011 Annual Meeting, the premier scientific meeting discussing the latest concepts and innovations in bone and mineral research, is being held September 16-20, 2011 in San Diego, California.  For more information, visit www.asbmr.org/Meetings/AnnualMeeting.aspx .

"Results of the ORACAL Trial: A Phase 3 Randomized Trial of the Safety and Efficacy of Orally Administered Recombinant Salmon Calcitonin Tablets in Postmenopausal Women with Osteoporosis," Neil Binkley MD, Michael Bolognese MD, James P Gilligan PhD, David S Krause MD.  Presented at the ASBMR 2011 Annual Meeting, Oral Session 23, 2:30pm PDT, September 18, 2011.

*The International Osteoporosis Foundation. Osteoporosis: The Inside Story. Fact sheet. Retrieved August 29, 2011, from

SOURCE Tarsa Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Tarsa Therapeutics Reports Positive Top-Line Results From Pivotal Phase III ORACAL Trial of its Oral Calcitonin in Treatment of Postmenopausal Osteoporosis
2. Tarsa Therapeutics Completes Phase III Trial of its Oral Calcitonin for Treatment of Postmenopausal Osteoporosis and Initiates Phase II Trial in Osteoporosis Prevention
3. Silence Therapeutics Announces Issuance of Japanese Patent for Screening Therapeutics Against Key Pathway Associated with Cancer and Other Diseases
4. Echo Therapeutics Receives Registered Trademarks for Symphony® and Prelude®
5. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the UBS 2011 Global Life Sciences Conference in New York City
6. ViroPharma and Halozyme Therapeutics Announce Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze® (C1 Esterase Inhibitor [Human]) with Hyaluronidase (rHuPH20)
7. Rare Disease Therapeutics, Inc. Selects Accredo Health Group to Distribute Anascorp® for the Treatment of Centruroides Scorpion Sting Envenomation
8. Silence Therapeutics and InteRNA Technologies Sign Collaboration to Develop Novel microRNA Therapeutics
9. Nile Therapeutics to Present at Rodman & Renshaw Global Investment Conference
10. Regulus Therapeutics to Present New Advancements in microRNA Therapeutics for Treatment of Metabolic Diseases and Cancer
11. Global Sepsis Therapeutics Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... 2014   Fruit Street Health (Fruit Street), ... round of funding. The round, which ... series of individual investors, the majority of whom are ... initial round are; Houston Cardiology Consultants Partner Asif ... Childs, Rapha Family Medicine Practice Owner Frances Ilozue ...
(Date:9/18/2014)... N.J. , Sept. 18, 2014  ADM ... Gianluca DeNovi , Ph.D. to its corporate Advisory ... is an instructor at the Harvard Medical School ... of Rome.  He received his Masters degree in ... Control Systems from the University of Bologna. After spending ...
(Date:9/18/2014)... MEETING, Pa. , Sept. 18, 2014 ... trial solutions, was recognized as the Disruptive ... for its ePharmaONE cloud-based eClinical platform. This ... and electronic trial master file (eTMF), a ... solution, and ePharmaSolutions, ReferralPlus+ patient screening and ...
Breaking Medicine Technology:Fruit Street Health Secures First Round Of Seed Funding Led By Group Of Medical Industry And Technology Leaders 2Fruit Street Health Secures First Round Of Seed Funding Led By Group Of Medical Industry And Technology Leaders 3ADM Tronics Appoints Gianluca DeNovi, Ph.D. To Advisory Board 2ADM Tronics Appoints Gianluca DeNovi, Ph.D. To Advisory Board 3ePharmaSolutions Named 2014 Disruptive Innovator of the Year for its ePharmaONE eClinical Platform 2ePharmaSolutions Named 2014 Disruptive Innovator of the Year for its ePharmaONE eClinical Platform 3
(Date:9/18/2014)... don,t worry, it,s a good thing! As scientists have ... bad. Many active enzymes and bacteria are merely benign, ... important part of our digestive system or can help ... an opportunistic yeast pathogen and model organism for research, ... ecosystem. However, when our immune system is stressed on ...
(Date:9/18/2014)... Non-governmental stakeholders will convene a one-day conference at ... George Washington University on September 25, 2014 to discuss ... towards GHSA implementation. The purpose of this event is ... over the next five years, including action plans to ... 2014 launch of the GHSA, international organizations and more ...
(Date:9/18/2014)... (September 18, 2014) The National Institutes of ... from a four-year, $1.3 million grant to the Los ... the research and development of a vaccine to protect ... Methicillin-resistant Staphylococcus aureus (MRSA). , The ... the NIH awarded the grant to LA BioMed infectious ...
(Date:9/18/2014)... DURHAM, N.C. Dangerous new pathogens such as the ... even ancient scourges such as the bubonic plague are ... body responds to infections. , In a study published ... , researchers at Duke Medicine and Duke-NUS Graduate Medical ... cause bubonic plague hitchhike on immune cells in the ...
(Date:9/18/2014)... ChopChop founder Sally Sampson is challenging former ... Massachusetts’s winner of the First Lady’s Healthy Lunchtime Challenge, to ... Eastern bean dip. Watch as Bill and Yonah cook side-by-side ... own healthy dips at home. The cooking demonstration will take ... Talk About Food Festival in Copley Square on September ...
Breaking Medicine News(10 mins):Health News:Everything in moderation: Micro-8 to study regulating pathogens in space 2Health News:Everything in moderation: Micro-8 to study regulating pathogens in space 3Health News:Non-governmental stakeholders to discuss the Global Health Security Agenda 2Health News:LA BioMed receives NIH grant to study vaccine for hospital-acquired infections 2Health News:New insights on an ancient plague could improve treatments for infections 2Health News:Award-Winning Cooking Magazine for Kids Challenges Former White House Pastry Chef and 10-Year-Old Chef to Cook Up a Healthy Snack 2Health News:Award-Winning Cooking Magazine for Kids Challenges Former White House Pastry Chef and 10-Year-Old Chef to Cook Up a Healthy Snack 3
... surveillance, planning and interagency coordinationWASHINGTON, May 8 Environmental ... the Natural Resources Defense Council (NRDC) praised legislation introduced ... climate change. The bill is sponsored by the ... Commerce Committee,s Subcommittee on Health , U.S. Rep. ...
... This Sunday, individuals all over the nation ... women who gave them life: their mothers. While people in ... International Breast Milk Project (IBMP) hopes to inspire some to ... that helps mothers in the United States send their breast ...
... Kaiser Foundation Health Plan, Inc., Kaiser Foundation Hospitals and ... $10.6 billion for the quarter ended March 31, 2009, ... year. Operating income in the first quarter was ... of 2008. Declines in the financial markets impacted ...
... May 8 Misonix, Inc. (Nasdaq: MSON ... technology, which in Europe is used for the ablation ... has entered into a definitive, 5-year distribution agreement with ... in Barcarena, Portugal, expanding on and replacing a previous ...
... - Majority have not changed their behavior or lifestyle ... May 8 A new national study among 1,477 ... become less concerned about the impact that the H1N1 ... http://www.newscom.com/cgi-bin/prnh/20071204/NYTU133LOGO )Results ...
... Family, Inc. (Nasdaq: AFAM ), a leading regional ... Yarmuth, President and Chief Executive Officer, and Steve Guenthner, Senior ... at two upcoming investor conferences. The first presentation will ... Stock Conference at the Four Seasons Hotel in Chicago, IL., ...
Cached Medicine News:Health News:New Bill to Fund Climate Change and Public Health Preparedness Praised by Environmental and Health Groups 2Health News:New Bill to Fund Climate Change and Public Health Preparedness Praised by Environmental and Health Groups 3Health News:New Bill to Fund Climate Change and Public Health Preparedness Praised by Environmental and Health Groups 4Health News:International Breast Milk Project Helps Mothers Worldwide 2Health News:Kaiser Foundation Health Plan and Hospitals Report First Quarter 2009 Financial Results 2Health News:Kaiser Foundation Health Plan and Hospitals Report First Quarter 2009 Financial Results 3Health News:Misonix Announces New HIFU Distribution Agreement For Portugal 2Health News:Misonix Announces New HIFU Distribution Agreement For Portugal 3Health News:Docs Are Becoming Less Concerned About H1N1 Swine Flu 2Health News:Docs Are Becoming Less Concerned About H1N1 Swine Flu 3Health News:Docs Are Becoming Less Concerned About H1N1 Swine Flu 4Health News:Almost Family to Present at Two Upcoming Conferences 2
For use with catalog #0540....
Lupus Anticoagulant-Sensitive APTT Reagent.Cephalin with particulate activator (silica), freeze-dried....
Antigenic Total Protein S, ELISA Method...
Colorimetric Assay of Antithrombin III Activity by STA© Analyzers. Bovine thrombin ~12NIH units/mL, freeze-dried....
Medicine Products: